There are 100 item(s) tagged with the keyword "Artemis".
Displaying: 1 - 10 of 100
The UK has been out of favour among international investors ever since 2016’s referendum on membership of the EU. But Artemis’ fund managers think this could be the year that all changes.
Natasha Ebtehadj, global equities fund manager, says that by investing billions of dollars in infrastructure, digitalising its finance system and reducing bureaucracy, India has overtaken China as investors’ favourite emerging market. But with valuations looking stretched, what is the best way to approach it?
Mark Niznik, manager of the Artemis UK Smaller Companies Fund, says that no one knows a business as well as the person running it, so it can be taken as a vote of confidence if they buy back its shares.
Swetha Ramachandran of the Artemis Funds (Lux) – Leading Consumer Brands Fund says onerous rules around which whisky is allowed to call itself ‘Scotch’ ensure established producers won’t be undercut by competitors who scrimp on costs or shift production to regions where labour is cheap.
Living fast and dying young may help rock stars achieve legendary status, but these traits are much less appealing when exhibited by potential investments, according to Mark Niznik of the Artemis UK Smaller Companies Fund.
Global equities managers Alex Stanić, Natasha Ebtehadj and Swetha Ramachandran reveal where they expect to find the biggest investment opportunities in 2024 and how they plan to make the most of them.
With interest on cash so high and markets looking volatile, some investors may be tempted to put their spare money in a standard savings account. However, doing so could come with a severe long-term opportunity cost.
Artemis’ fixed income team share their three key messages for 2024.
Raheel Altaf, manager of the Artemis SmartGARP Global Emerging Markets Equity Fund, explains why he is overweight China despite the well-publicised risks, but underweight more ‘fashionable’ regions such as India and Taiwan.
Through share buybacks, some of the best companies in the UK market are delivering compound growth in their earnings per share – and so rewarding their patient shareholders.
Displaying: 1 - 10 of 100